Table 4.
Univariate analysis of overall survival (OS)
| At 1 year (%) | At 3 years (%) | P | |
|---|---|---|---|
| Radiochemotherapy regimen | |||
| Cisplatin weekly (N = 75) | 71 | 45 | |
| Cisplatin 100 mg/m2 (N = 58) | 83 | 60 | 0.026 |
| Age | |||
| ≤56 years (N = 67) | 77 | 54 | |
| ≥57 years (N = 66) | 74 | 49 | 0.50 |
| Gender | |||
| Female (N = 29) | 89 | 70 | |
| Male (N = 104) | 72 | 47 | 0.050 |
| ECOG Performance score | |||
| 0–1 (N = 115) | 78 | 56 | |
| 2 (N = 18) | 61 | 14 | 0.006 |
| Primary tumor site | |||
| Oropharynx (N = 69) | 78 | 61 | |
| Hypopharynx (N = 19) | 53 | 21 | |
| Larynx (N = 30) | 83 | 59 | |
| Oral cavity/Floor of mouth (N = 15) | 80 | 29 | <0.001 |
| T-category | |||
| T1–2 (N = 16) | 81 | 63 | |
| T3–4 (N = 117) | 75 | 50 | 0.85 |
| N-category | |||
| N0-2a (N = 66) | 79 | 60 | |
| N2b-3 (N = 67) | 73 | 42 | 0.14 |
| Histologic grading | |||
| G 1–2 (N = 85) | 78 | 52 | |
| G3 (N = 48) | 73 | 51 | 0.47 |
| Cumulative cisplatin dose | |||
| ≤ 200 mg/m2 (N = 85) | 69 | 46 | |
| > 200 mg/m2 (N = 48) | 87 | 61 | 0.13 |
After Bonferroni correction for multiple tests, p-values of <0.006 were considered significant
Bold values represent significant p-values